Home
Company
Therapeutic Focus
Pipeline
UNI-494
Renazorb
Investors
Resources
Contact
All SEC Filings
Investors
Investors
Overview
News
Events & Presentations
IR Calendar
Presentations
Governance
Overview
Management Team
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Financial & Stock Info
Overview
Financial Results
Quote
Charts
Historical Data
Analyst Coverage
Resources
Overview
Contacts
FAQ
Email Alerts
Filing Type:
View All
10-K
10-Q
3
4
4/A
424B3
424B4
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
NT 10-Q
PRE 14A
S-1
S-1/A
S-3
S-8
SC 13G
SC 13G/A
SEC STAFF LETTER
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
Date
Form
Description
PDF
XBRL
Pages
05/21/21
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-3.4
EX-3.5
EX-4.1
EX-10.3
EX-10.7
EX-10.8
EX-10.9
EX-10.10
EX-23.1
183
05/10/21
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
2
04/29/21
DRSLTR
Correspondence Related to Draft Registration Statement
1
04/29/21
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-3.1
EX-3.2
EX-3.3
EX-10.1
EX-10.2
EX-10.4
EX-10.5
EX-10.6
205
03/17/21
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
2
02/18/21
DRSLTR
Correspondence Related to Draft Registration Statement
2
02/18/21
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
77
11/10/20
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
2
11/02/20
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
121
09/15/20
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
121
rss_feed
Filing RSS
arrow_back
1…
9
10
11
12
13
14
15
16
17
18
arrow_forward
Email Alerts
Contacts
RSS News Feed